When looking at the biopharmaceutical it is hard to come up with an intrapreneurial opportunity since I am certainly no bio-pharmacists. After some thought and research one great opportunity that a company like SOBI could invest in, is an alternative dose for their most popular selling medicine Kineret. I say an alternate dose because, the current dosage that Kineret comes in is only 100ml syringes. Not all cliental need that large of a dosage, for example children require about half the dosage. With smaller dosage syringes, it could cost the consumer less and the medicine would not be just poured down the drain, since you cannot reuse a needle. Initially this seems like just an easy fix, but we must look at the level of effort and resources needed to determine whether this is a profitable move for the company. SOBI and it’s product Kineret serve both adults and adolescences. The company has seen an increase in children’s using the product by 25 percent. This number is expected to grow 15 percent, and all of these children do not need the 100mL that is filled for the adults (SOBI). Children taking the medication generally have a dose of 50mL or less. By decreasing this dosage the company could charge less …show more content…
For the new clinical trials we are looking at roughly 15 million, with the cost of new packaging for the first million units, to be 2.5 million and the cost of new marketing 100 million. The total is roughly 117.5 million dollars for this new venture. The potential growth rate is 25% with children taking Kineret. The company made 4.5 Billion dollars and with a 25% increase at a reduce rate of 1,500 per unit would make the company roughly 600 million dollars. 600 million dollars minus the cost of the new venture 117.5 million leaving the company with about a profit of 482.5 million dollars. This sound like it might be a venture worth looking
Memorial Sloan Kettering Cancer Center (MSKCC) has impacted the world nationally and internationally for their involvement and work with cancer, science, research, and medicine. A goal of Memorial Sloan Kettering Cancer Center (MSKCC) is through extensive research and training explore new ways to treat, cure, and control cancer on a national and worldwide level. Scientist and Researchers affiliated with MSKCC take their knowledge, investigation, and research to create clinical trials, studies and new treatments for cancer nationally and worldwide which create various economic opportunities throughout the nation and world.
In the recent years the drug industry underwent a significant transformation. Many of the big companies generate high revenues, which allow them to expand. Some of them expand on their own others through mergers and the buying of smaller companies.
Knudstrop came to Lego at a time when Lego was losing a substantial amount of money, this eventually equated to nearly $1 million per day (Weiners). This was in part due to the fact that the strategy that was implemented in the past was doing more harm than good as the years progressed. One hindrance the company faced prior to the arrival of Knudstrop was that the company was continuing at add more bricks to their toys, this created the issue of products becoming harder to assemble, forecasts harder to determine, and inventory increasingly harder and more difficult to manage (Starvish). Depending on the kit, there was either too much inventory, or not enough inventory at all, and restocking could take months (Starvish).
...ll help the company in selling generic drugs and provide affordable medications to its customer base.
D.U. Singer Hospital Products Corp. has done sufficient new product development at the research and development level to estimate a high likelihood of technical success for a product of assured commercial success: A long-term antiseptic. Management has instructed Singer’s Antiseptic Division to make a market entry at the earliest possible time: they have requested a complete plan up to the startup of production. Marketing and other plans following startup of production are to be prepared separately after this plan has been completed.
Before moving on with clinical testing phase, Nucleon management is evaluating advantages and disadvantages for 3 main manufacturing strategies for the company. For Phase I and II these options are 1) building a new 5000-sq pilot plant supplying CRP-1 needed for Phases I and II, 2) contracting clinical manufacturing to an outside firm, and 3) licensing the manufacturing to another biotech or pharmaceutical firm. If CRP-1 succeeds in the first two phases, there are two more options available to the company for Phase III, that are 1) vertical integration to commercial marketing and 2) licensing manufacturing and marketing.
In 2000, Rich Kender, Vice President of Financial Evaluation and Analysis at Merck & Company was discussing the opportunity of investing in licensing, manufacturing and marketing of Davanrik, a drug originally developed to treat depression by LAB Pharmaceuticals. LAB proposed to sell the right of all the future profit made from the successful launch of Davanrik at the cost of an initial fee, royalty payments and additional payments as the drug completed each stage of the approval process. Merck & Company's organizational goal is to constantly refresh it's company's drug development portfolio and reach as many customers as possible during the patented time. So there was not only the potential of financial gain or quantitative aspect of the offer, but also the qualitative value which will be added by getting better positioning in the risky pharmaceuticals industry.
In the business of drug production over the years, there have been astronomical gains in the technology of pharmaceutical drugs. More and more drugs are being made for diseases and viruses each day, and there are many more drugs still undergoing research and testing. These "miracle" drugs are expensive, however, and many Americans cannot afford these prices.
additional funds that could be used for awareness of the drugs affects and treatment. We would
Spurgeon, P., Burke, R. J., & Cooper, C. L. (2012). The innovation imperative in health care
6) mentions some critics argue that treating patients should not be considered a business. These critics argue that these initiatives have the chance of negatively affecting patient treatment and “care as the quest for achieving enhanced operational performance may dictate procedures” (Kudyba, 2010, p. 6). I do see where these critics are coming from however, look how far medicine has come and how much has improved. These new protocols and business models are extremely beneficial to not only the hospitals but to the patients, as well. Most nurses and doctors came into this business to help people. Just because they have to follow a specific business model doesn’t change their heart. These protocols have the ability to improve patient weight time, improve care protocols, which saves time and money for both parties, and save lives. There really is no other way to go about this besides treating it as a
Over the past decade, scientists have made significant advancements in the treatment of certain diseases. Unfortunately, just like any new product, the cost of developing these new technologies and treatments is extremely high. Plus, unlike other technology, heath technolo...
... of the changes because it will not require going through the entire upper management team for approval as they are already the ones on the review teams.
All these improvements will boost profitability by identifying at least or more that EUR 30 mio required by U.S.A headquarters. However, we believe it is not realistic to manage all this turnaround in 1 year’s time. It might take from 2 – 3 years.
also be fixed with effort from the management, with potential to turn undercapitalized resources and